<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621915</url>
  </required_header>
  <id_info>
    <org_study_id>KE 0254/23/2021</org_study_id>
    <nct_id>NCT05621915</nct_id>
  </id_info>
  <brief_title>Nadroparin Pharmacokinetics in Different Stages of COVID-19</brief_title>
  <official_title>Nadroparin Pharmacokinetics in Different Stages of COVID-19-a Prospective Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Lublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:&#xD;
&#xD;
      The risk of thrombotic complications in critical COVID-19 patients remains extremely high,&#xD;
      and multicenter trials failed to prove the survival benefit of escalated doses of low&#xD;
      molecular weight heparins (LMWH) in this group. The aim of this study was to develop a&#xD;
      pharmacokinetic model of LMWH (nadroparin calcium) according to different stages of COVID-19&#xD;
      severity.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      The investigators performed a prospective observational study.&#xD;
&#xD;
      Patients:&#xD;
&#xD;
      Blood samples were obtained from 43 COVID-19 patients that received nadroparin and were&#xD;
      treated with conventional oxygen therapy, mechanical ventilation, and extracorporeal membrane&#xD;
      oxygenation.&#xD;
&#xD;
      Setting:&#xD;
&#xD;
      The investigators recorded clinical, biochemical, and hemodynamic variables during 72 hours&#xD;
      of treatment. The analyzed data comprised 782 serum nadroparin concentrations and 219&#xD;
      anti-factor Xa levels. The investigators conducted population nonlinear mixed-effects&#xD;
      modeling (NONMEM) and performed Monte Carlo simulations of the probability of target&#xD;
      attainment (PTA) for reaching 0.2-0.5 IU/ml anti-Xa levels in study groups.&#xD;
&#xD;
      Interventions: None.&#xD;
&#xD;
      Measurements and Main Results:&#xD;
&#xD;
      The investigators successfully developed a one-compartment model to describe the population&#xD;
      pharmacokinetics of nadroparin in different stages of COVID-19.&#xD;
&#xD;
      Conclusions:&#xD;
&#xD;
      Different nadroparin dosing is required for patients undergoing mechanical ventilation and&#xD;
      ECMO to achieve the same targets as those for non-critically ill patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Actual">April 15, 2022</completion_date>
  <primary_completion_date type="Actual">February 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nadroparin concentration in blood measurement</measure>
    <time_frame>6 hours</time_frame>
    <description>Sequential measurement every 6 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in anti-Xa serum level</measure>
    <time_frame>12 hours</time_frame>
    <description>Sequential measurement every 12 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of nadroparin</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of nadroparin</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption rate of nadroparin</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Thrombosis</condition>
  <condition>Nadroparin</condition>
  <condition>COVID-19</condition>
  <condition>Mechanical Ventilation</condition>
  <condition>Anticoagulants and Bleeding Disorders</condition>
  <arm_group>
    <arm_group_label>conventional oxygen therapy</arm_group_label>
    <description>Patients treated with conventional oxygen in Infectious Diseases Ward.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mechanical ventilation</arm_group_label>
    <description>Patients who are mechanically ventilated and treated in ICU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mechanical ventilation and ECMO</arm_group_label>
    <description>Patients who are mechanically ventilated and on ECMO treated in ICU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadroparin</intervention_name>
    <description>Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.</description>
    <arm_group_label>conventional oxygen therapy</arm_group_label>
    <arm_group_label>mechanical ventilation</arm_group_label>
    <arm_group_label>mechanical ventilation and ECMO</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        First group (Group 1) consisted of 14 patients treated with conventional oxygen therapy&#xD;
        only in the infectious diseases department. The second group (Group 2) consisted of 14&#xD;
        mechanically ventilated patients treated in the ICU, and the third group (Group 3) was&#xD;
        formed by 15 patients supported with extracorporeal membrane oxygenation (ECMO) and&#xD;
        mechanically ventilated in the ICU. The investigators used surviving sepsis campaign&#xD;
        guidelines for COVID-19 for the escalation of treatment in the study population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients treated in the Department of Anesthesiology and Intensive Care and the&#xD;
             Department of Infectious Diseases of a tertiary academic hospital with confirmed&#xD;
             SARS-CoV-2 infection with a real-time reverse transcription polymerase chain reaction&#xD;
             (RT-PCR) or an antigen test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coagulation disorders at the start of the therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Paweł Piwowarczyk, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Lublin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2nd Department of Anesthesiology and Critical Care, Medical University of Lublin</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-059</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Lublin</investigator_affiliation>
    <investigator_full_name>Paweł Piwowarczyk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nadroparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

